Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial
Gilead’s experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.
The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million adults in the U.S....
Tigeraire, a company that makes cooling products for athletes, said Sun Day Red and Tiger Woods have "unlawfully hijacked" Tigeraire's...
Local fans of the Denver Nuggets and Colorado Avalanche will have more options to watch both teams this season.
According to a UBS survey of investors with at least $1 million of investible assets, 57% plan to vote for...
Sales are expected to fall roughly 2% during the third quarter compared to the same time in 2023 to about...
Veteran journalist and "TODAY" fourth-hour host Hoda Kotb announced she will be leaving the show early next year.